Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan

Documenti analoghi

• Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study
  di: Yasuyuki Komiyama, et al.
  Pubblicazione: (2025)
• Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group
  di: Keiji Tsuji, et al.
  Pubblicazione: (2025)
• Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy
  di: Toshifumi Tada, et al.
  Pubblicazione: (2024)
• Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2026)
• Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2025)